Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

47
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
47
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

51
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
51
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

28
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
28
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

42
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
42

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Tetralogy of Fallot: electrophysiology-guided surgical ablation during pulmonary valve replacement.

European heart journal·2026
Same author

One-Year Outcomes of the First 1000 Patients Implanted With the Medtronic Micra AV Leadless Pacing System in France: The AV-CESAR Cohort Study.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Quantification of Tricuspid Valve Regurgitation With 2D and 4D-Flow MRI: Comparison of Different Methods in Adult Patients With Ebstein's Anomaly.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Correction: <i>BAG3</i>-related myofibrillar myopathy: focus on its cardiac involvement.

Frontiers in genetics·2026
Same author

Irritative ventricular tachycardia after transcatheter pulmonary valve replacement.

European heart journal. Case reports·2026
Same author

Strategies for preventing arrhythmic sudden death in adult congenital heart disease.

European heart journal supplements : journal of the European Society of Cardiology·2026

関連する実験動画

Updated: Sep 10, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K

乳児におけるアクセサリー経路媒介の拡張性心筋病

Claire Bertail-Galoin1, Nabil Jbilou1, Victor Waldmann2

  • 1Felix Guyon Hospital Center, CHU La Réunion, Competence Center for Complex Congenital Heart Disease - M3C, Saint-Denis, France.

Cardiology in the young
|August 26, 2025
PubMed
まとめ

10ヶ月の乳児の拡張心筋病は,補助経路の前刺激によって引き起こされた隔膜不協和症の治療によって解消されました. フレカニド療法は,前刺激を排除することによって左心房機能を正常化させた.

キーワード:
付属経路心筋病左バンドルのブランチブロック前刺激

さらに関連する動画

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

関連する実験動画

Last Updated: Sep 10, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

科学分野:

  • 小児心臓科
  • 電気生理学
  • 心筋病の研究

背景:

  • 胎盤不協和症は乳児の拡張性心筋病を引き起こす可能性があります.
  • 付属経路は心臓の電気異常を 引き起こします
  • 興奮前症候群は,明白な高心率なしに現れます.

研究 の 目的:

  • 補助経路の前刺激に関連した乳児の拡張性心筋病症の症例を記述する.
  • 隔膜同期と心室機能に対する前刺激の影響を調査する.
  • この状態の管理におけるフレカニドの有効性を評価する.

主な方法:

  • 10ヶ月の赤ん坊の 拡大心筋症の症例報告
  • 前刺激と不協調性を特定するために,心電図 (ECG) の分析.
  • 左心室の機能の評価
  • フレカニドによる治療

主要な成果:

  • 乳児は右側隔膜の補助経路から左側隔膜の不協和に起因する 拡張性心筋症候群を呈した.
  • 心房回転性早心症は観察されなかった.
  • フレカニド療法は,ECGでのアンテグラード前刺激を成功裏に排除した.
  • 左心室の機能は治療後に正常化しました.

結論:

  • 附属経路による前刺激は,乳児において重大な隔膜不協和症および拡張心筋病を引き起こす可能性があります.
  • 早期診断とフレカニドなどの標的型抗リズム療法により,心臓機能不全を逆転させることができます.
  • このケースは,小児心筋病における電気生理学的異常を考慮する重要性を強調しています.